Edwards Lifesciences Corp (EW) - Total Liabilities
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has total liabilities worth $2.99 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Edwards Lifesciences Corp - Total Liabilities Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's total liabilities have evolved over time, based on quarterly financial data. See Edwards Lifesciences Corp (EW) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Edwards Lifesciences Corp Competitors by Total Liabilities
The table below lists competitors of Edwards Lifesciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Investor AB ser. A
ST:INVE-A
|
Sweden | Skr148.91 Billion |
|
Cathay Financial Holding Co Ltd
TW:2882
|
Taiwan | NT$13.63 Trillion |
|
Cencora Inc.
NYSE:COR
|
USA | $78.07 Billion |
|
Rockwell Automation Inc
NYSE:ROK
|
USA | $7.68 Billion |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
Germany | €262.65 Billion |
|
Discover Financial Services
NYSE:DFS
|
USA | $128.95 Billion |
|
Ambev S.A.
SA:ABEV3
|
Brazil | R$54.79 Billion |
|
MetLife Inc
NYSE:MET
|
USA | $715.41 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Edwards Lifesciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EW market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edwards Lifesciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual total liabilities of Edwards Lifesciences Corp from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.36 Billion | +12.27% |
| 2024-12-31 | $2.99 Billion | +13.19% |
| 2023-12-31 | $2.64 Billion | +6.36% |
| 2022-12-31 | $2.49 Billion | -6.78% |
| 2021-12-31 | $2.67 Billion | +0.15% |
| 2020-12-31 | $2.66 Billion | +13.80% |
| 2019-12-31 | $2.34 Billion | +7.17% |
| 2018-12-31 | $2.18 Billion | -19.19% |
| 2017-12-31 | $2.70 Billion | +42.88% |
| 2016-12-31 | $1.89 Billion | +21.51% |
| 2015-12-31 | $1.56 Billion | +16.75% |
| 2014-12-31 | $1.33 Billion | +14.36% |
| 2013-12-31 | $1.17 Billion | +57.03% |
| 2012-12-31 | $742.20 Million | +15.50% |
| 2011-12-31 | $642.60 Million | +40.00% |
| 2010-12-31 | $459.00 Million | +0.31% |
| 2009-12-31 | $457.60 Million | -12.24% |
| 2008-12-31 | $521.40 Million | +2.22% |
| 2007-12-31 | $510.10 Million | +2.55% |
| 2006-12-31 | $497.40 Million | -7.74% |
| 2005-12-31 | $539.10 Million | +11.25% |
| 2004-12-31 | $484.60 Million | +3.92% |
| 2003-12-31 | $466.30 Million | -0.53% |
| 2002-12-31 | $468.80 Million | -8.79% |
| 2001-12-31 | $514.00 Million | -20.68% |
| 2000-12-31 | $648.00 Million | +204.23% |
| 1999-12-31 | $213.00 Million | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more